Virax Biolabs Group Ltd. has unveiled its latest investor presentation, focusing on its efforts to develop next-generation immune diagnostics for chronic inflammation and immune dysfunction. The company, listed on NASDAQ under the ticker VRAX, is in the commercialization phase with a portfolio of immunology research tools. The presentation highlights their ViraxImmuneTM platform, which is designed to support drug development, immune monitoring, and disease mechanism research. It outlines a dual-platform strategy that includes diagnostics and research solutions, aiming to address post-acute infection syndromes, protective immunity, and immuno-oncology. Virax Biolabs is conducting clinical trials in the UK and US, with a focus on providing actionable cellular immunity diagnostics for conditions like Long COVID and ME/CFS. The presentation emphasizes the urgent need for tools to detect immune dysfunction and to support clinical decision-making. You can access the full presentation through the link below.